C3 Jian, Inc. Announces Todd Patrick New CEO
Published: Nov 18, 2010
“My tenure as CEO has been very satisfying in terms of what we have accomplished, and I am honored to have worked closely with so many talented professionals at C3 Jian”
“Todd’s expertise in biopharmaceutical management and strategic financing make him the perfect person to lead us in this next phase, and we’re very pleased to have him join the organization as CEO,” said James Garrison, Chairman of the Board for C3 and retired President and CEO of Washington Dental Service. “He will focus the company on its core competencies in areas of business that will have the greatest impact on corporate growth moving forward.”
“I am delighted to take part in this opportunity to apply my experience in the development and commercialization of biopharmaceutical products to C3’s exciting technology capabilities,” said Patrick. “I’ll focus on creating a strategic and financial platform to further advance the company’s novel products for the diagnosis and treatment of infectious disease.”
Formerly, Mr. Patrick became President, Chief Operating Officer, and Director of ID Biomedical Corporation in 1998 after the Company elected to exit its core diagnostic business to focus on vaccines. Mr. Patrick started ID Biomedical’s vaccine subsidiary in 1994. In September 2005, GlaxoSmithKline purchased ID Biomedical for approximately $1.5 billion. To date, the GSK/IDB merger is the largest "pure play" enterprise value M&A transaction in the history of the vaccine industry. Prior to joining ID Biomedical, Mr. Patrick was the first Director of the Office of Intellectual Property Administration at the University of California, Los Angeles (UCLA). Mr. Patrick joined UCLA to help form its new IP program in 1989. Mr. Patrick serves as a director for several biomedical and device companies. He is also a current or past trustee of a variety of organizations in the Pacific Northwest, including the Seattle Biomedical Research Institute (Chairman of the Board), Washington Biotechnology and Biomedical Association (WBBA), and the WSU Research Foundation.
Mr. Patrick joined the board of directors of C3 in late 2009.
Garrison adds, “Max’s leadership as President and CEO has been important to our success thus far, and we look forward to working with him as the Company’s Special Advisor.” Dr. Anderson was a co-Founder of C3 and served as President and CEO since the company’s inception. Dr. Anderson is a licensed dentist and dental researcher whose current responsibilities include dental consulting to the insurance industry.
“My tenure as CEO has been very satisfying in terms of what we have accomplished, and I am honored to have worked closely with so many talented professionals at C3 Jian,” stated Dr. Anderson. “I am excited about our future as I pass the reigns over to Todd, and I look forward to continued work with the Board and the management team as we continue to build value.”
About C3 Jian, Inc.
C3 Jian, founded in 2005, is a clinical-stage biotechnology company developing and commercializing novel products to diagnose, treat and prevent human and animal diseases. C3’s lead compounds are focused on selective treatment of bacterial and fungal infections, disorders of mineralization, and reversing hair loss. C3 is advancing targeted solutions, including both diagnostics and therapeutics, which will offer more selective, efficacious and safer treatment modalities for a variety of diseases and disorders. C3 Jian is based in Los Angeles, California. For more information about the company, please visit www.c3-jian.com.
For C3 Jian, Inc. Stacie D. Byars, 206-660-2588 firstname.lastname@example.org Justin Hsiao, 310-665-2928 x206 email@example.com